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Abstract 
BACKGROUND: Keloids are dermal fibroproliferative tumours characterised by excessive deposition of extra 
cellular matrix components. The active form of vitamin D is known to inhibit the proliferation of keloid fibroblasts by 
inhibiting extracellular matrix production induced by transforming growth factor ß (TGF-β) and increasing matrix 
metalloproteinase (MMP) activity. Vitamin D derivatives are thought to be an early preventive treatment strategy 
for keloid. 
AIM: To determine the correlation between serum 25-hydroxyvitamin D level with keloid severity. 
METHODS: This is a cross-sectional analytic study involving 32 keloid patients. Keloid patients were diagnosed 
by history and clinical examinations. Then an assessment of the severity was conducted using the Vancouver 
Scar Scale (VSS). We conducted blood sampling and measurement of serum 25-hydroxyvitamin D level to the 
patients. This study has been approved by the Health Research Ethics Commission of the Faculty of Medicine, 
Universitas Sumatera Utara, H. Adam Malik General Hospital Medan. 
RESULTS: There is negative correlation between serum 25-hydroxyvitamin D level with severity in keloid patients 
(p = 0.0001; r = -0.737). There is no significant correlation between serum 25-hydroxyvitamin D level with gender 
(p = 0.271), age (p = 0.201; r = -0.232), duration of keloid (p = 0.505; r = -0.122) and family history (p = 0.262). 
CONCLUSION: Lower level of plasma 25-hydroxyvitamin D, the severity of keloid became an increasingly heavy. 
There is no significant difference between serum 25-hydroxyvitamin D level with gender, age, duration of keloid 
and family history in keloid patients. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Keloid is dense fibrous tumours that develop 
from abnormal responses to skin injuries restoration. 
Keloid is a pathologic scar that extends beyond the 
boundary of the wound, benign and has no potential 
for malignancy [1], [2]. Keloid is dermal 
fibroproliferative tumours characterised by excessive 
deposition of extracellular matrix components [2].  
The 25-hydroxyvitamin D level which is the 
main form of vitamin D in the circulation and this 
molecule is a measure for assessing vitamin D status 
in the body [3]. It is known that vitamin D has a 
beneficial role in slowing the progression of tissue 
fibrosis [4], [5], [6]. The active form of vitamin D is 
known to inhibit the proliferation of keloid fibroblasts 
by inhibiting extracellular matrix production induced by 
TGF-β and increasing MMP activity and acting as an 
anti-inflammatory mediator [7].  
Vancouver Scar Scale is one of the most 
widely used scarring scoring systems in clinical 
research. This scale assesses four variables: 
vascularisation, pigmentation, consistency, and 
height/thickness [8], [9].
 
It is known that each of this 
variable is relevant to untreated keloid scar [9].
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Methods 
 
This study was conducted from January 2018 
to September 2018. This study was a cross-sectional 
analytical study involving 32 keloid patients who had 
been diagnosed with keloid by history and clinical 
examination at the Universitas Sumatera Utara, 
Medan, Indonesia, with an age of 16-40 years. Every 
subject who had signed informed consent was 
included in this study. Exclusion criteria were 
pregnancy, hormonal disorders including thyroid and 
parathyroid disease; kidney and liver disease, 
systemic diseases including cardiovascular disease, 
diabetes mellitus, and tuberculosis and malignancy; 
autoimmune diseases including psoriasis, systemic 
lupus erythematosus, and scleroderma; long-term 
history of anti-seizure medication, antibiotic and 
antiviral drugs such as phenobarbital, phenytoin, 
carbamazepine, rifampicin, and antiretroviral; there is 
a history of conventional treatment for keloids such as 
triamcinolone acetonide injection, topical 
corticosteroids, cryosurgery, radiation, laser, occlusive 
dressings, compression therapy and interferon in the 
past two months; and consuming any vitamin D 
supplementation in the past 1 month. This study has 
been approved by the Health Research Ethics 
Committee of the Faculty of Medicine, Universitas 
Sumatera Utara. In all study subjects, we assessed 
the severity of keloid using VSS and blood samples 
were taken for measurement of serum 25-
hydroxyvitamin D level. 
The results were analysed statistically by the 
Spearman correlation test. This test was used to 
investigate the relationship between the level of serum 
25-hydroxyvitamin D with keloid severity. 
 
 
Results 
 
Most of the subjects involved in this study 
were women, aged 21-25 years, suffered from keloid 
for 1-5 years, had no family history of keloid, and 
moderate keloid severity (Table 1). 
Table 1: Subjects and characteristic 
Variable n % 
Gender   
Male 8 25.0 
Female 24 75.0 
Age   
16-20 years 6 18.8 
21-25 years 13 40.6 
26-30 years 2 6.3 
31-35 years 3 9.4 
36-40 years 8 25.0 
Duration of disease   
1-5 years 23 71.9 
6-10 years 4 12.5 
11-15 years 1 3.1 
16-20 years 4 12.5 
Family history   
Father 1 3.1 
Mother 2 6.3 
Sibling 9 28.1 
None 20 62.5 
Severity   
Mild 2 6.3 
Moderate 16 50.0 
Severe 14 43.8 
Statistically, there was a negative correlation 
between serum 25-hydroxyvitamin D level, and keloid 
severity (p = 0.0001, r = -0.737), the lowest level of 
serum 25-hydroxyvitamin D in this study subject was 
in severe-degree (VSS 10-14) is 12.34  2.61 ng/mL 
(Table 2). 
Table 2: Serum 25-hydroxyvitamin D level based on the 
severity 
Severity 
Serum 25-hydroxyvitamin D level (ng/mL) 
n Mean SD Min Max 
Mild 2 26.95 0.78 26.40 27.50 
Moderate 16 20.98 5.19 6.90 27.40 
Severe 14 12.34 2.61 6.60 16.60 
 
In Table 3, there was no significant 
relationship between serum 25-hydroxyvitamin D level 
with gender (p = 0.271), age (p = 0.201; r = -0.232), 
duration (p = 0.505; r = -0.122), and family history (p = 
0.262). 
Table 3: Relationship between serum 25-hydroxyvitamin D 
level with gender 
 
Serum 25-hydroxyvitamin D level (ng/dL) 
n Mean SD p 
Gender     
0.271 Male 8 19.73 4.73 
Female 24 16.85 6.70 
Family history     
Present 12 19.22 6.83 0.262 
None 20 16.60 5.95 
 
 
 
Discussion 
 
The active form of vitamin D is known to 
inhibit the proliferation of keloid fibroblasts by 
inhibiting extracellular matrix production induced by 
transforming TGF-β and increasing MMP activity [7]. 
In this study, there was a negative correlation 
between serum 25-hydroxyvitamin D level with keloid 
severity. The negative correlation indicates that the 
lower the serum 25-hydroxyvitamin D level, the more 
severe the degree of the keloid. The results of this 
study are by the research conducted by Medikawati et 
al., which found a negative correlation between 
plasma 25-hydroxyvitamin D level and the severity in 
keloid subjects (r = -0.584; p < 0.001) [10]. Study on 
the correlation of serum 25-hydroxyvitamin D level in 
keloid is still scarce, but in the study by Zhang et al., 
found the presence of VDR in keloid fibroblasts 
culture and incubation of keloid fibroblasts with 1.25-
dihydroxy vitamin D suppresses TGF-β1 which 
induces type I collagen, fibronectin, and α-SMA 
expression [11]. Also, several studies have shown that 
the Nuclear Transcription Factor-kB (NF-kB) signalling 
pathway is activated in keloid fibroblasts, whereas it is 
known that vitamin D has a role in regulating 
inflammation through inhibition of NF-kB. This 
contributes to the idea that vitamin D can inhibit the 
inflammatory process as occurs in keloid [12]. 
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There was no significant relationship between 
serum 25-hydroxyvitamin D level and the gender of 
keloid patients in this study. The authors have not 
found a study discussing the relationship between 
serum 25-hydroxyvitamin D level with gender in keloid 
patients, but in a study by Yu et al., it was found that 
gene polymorphisms from vitamin D receptors 
affected the level of serum 1.25-hydroxyvitamin D and 
on stratification analysis based on gender found that 
this tendency only exists in the female subject but not 
in the male subject [4].  
In this study, there was no significant 
relationship between serum 25-hydroxyvitamin D level 
and the age of keloid patients. According to Hagenau 
et al., study of the global serum 25-hydroxyvitamin D 
status in the general population, it was found that the 
lowest serum 25-hydroxyvitamin D level was at an 
age group of ≤ 15, and the highest was at the age 
group of 66-75 years, but there was no significant 
relationship between the level 25-hydroxyvitamin D 
with age [13]. 
In this study, there was no significant 
relationship between the level of serum 25-
hydroxyvitamin D and the duration of the keloid. It is 
known that there is a role for vitamin D in the 
pathogenesis of keloid, but the authors have not found 
literature discussing the relationship between the level 
of serum 25-hydroxyvitamin D and the duration of the 
keloid. To determine whether there is a role for 
vitamin D in the course of the duration of the disease 
requires further research.  
This study also found no relationship between 
the level of serum 25-hydroxyvitamin D with a family 
history. In a study by Lu et al., which analysed the role 
of family history of keloid, the highest keloid severity 
was observed in subjects with a positive family 
history, and the risk for the occurrence of keloid in the 
first-degree relative was 72.45%. These results 
indicate that genetic factors play an important role in 
the occurrence of the keloid [14].  
In conclusion, the lower level of serum 25-
hydroxyvitamin D, the greater the severity of keloid, 
there was no correlation between serum 25-
hydroxyvitamin D level with gender, age, duration, and 
family history of the keloid. Further studies are needed 
to determine the benefits of vitamin D derivatives 
administration to keloid patients, as a basis for 
consideration of additional therapy in the management 
of keloid in health services. 
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